Therapy of Childhood Acute Nonlymphocytic Leukemia: The Pediatric Oncology Group Experience (1977–1988)
In 1977, the members of the Pediatric Oncology Group (POG, formerly the Pediatric Division of the Southwest Oncology Group) initiated a series of protocols designed for the investigation and therapy of childhood acute nonlymphocytic leukemia (ANLL). In general, studies of childhood ANLL prior to the early 1970s were concerned primarily with induction response rates. Those studies usually employed single agents or drug combinations which had proven effective for the more frequently occurring acute lymphocytic leukemia of childhood.
KeywordsLeukemia Oncol Methotrexate Prednisone Etoposide
Unable to display preview. Download preview PDF.
- 9.Steuber CP, Civin C, Culbert S et al. Therapy of childhood acute nonlymphocytic leukemia (ANLL) A Pediatric Oncology Group study, (in preparation)Google Scholar
- 10.Ravindranath Y, Krischer J, Steuber P et al. (1988) High dose arabinosyl cytosine (HdA) for induction and consolidation in childhood acute non-lymphocytic leukemia (ANLL) — A Pediatric Oncology Group study. International Society of Paediatric Oncology (SIOP), XX Meeting, Trondheim, Norway, Aug. 22–26, 1988, p 91 (abstract) published in: Med Pediatr Oncol 16: 408Google Scholar
- 13.Woods WG, Ruymann F, Lampkin BC et al. (1987) Aggressive intensification treatment may abrogate the need for maintenance therapy in children with acute nonlymphocytic leukemia (ANLL). Blood 70 (Suppl l): 241a (abstract)Google Scholar
- 14.Kalwinski D, Mirro J, Jr, Schell M et al. (1988) Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five drug regimen including etoposide. J Clin Oncol 6: 1134Google Scholar
- 15.Creutig U, Ritter J, Riehm H et al. (1985) Improved results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood 65: 298Google Scholar
- 19.Creutzig U, Ritter J, Schellong G (1988) Improved treatment results in the myelocytic subtypes FAB Ml -M4 due to intensification of induction therapy in the German AML- Study BFM-83. International Society of Paediatric Oncology (SIOP), XX Meeting Aug 1988 (abstract)Google Scholar